| Assessment Status | Rapid Review complete |
| HTA ID | 20009 |
| Drug | Brolucizumab |
| Brand | Beovu® |
| Indication | Treatment of neovascular (wet) age-related macular degeneration. |
| Assessment Process | |
| Rapid review commissioned | 26/02/2020 |
| Rapid review completed | 07/04/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical and cost effectiveness of brolucizumab compared with the current standard of care. |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.